Immunological responses following administration of a genotype 1a/1b/2/3a quadrivalent HCV VLP vaccine
Files
(Published Version)
Date
2018
Authors
Christiansen, D.
Earnest-Silveira, L.
Chua, B.
Meuleman, P.
Boo, I.
Grubor-Bauk, B.
Jackson, D.
Keck, Z.
Foung, S.
Drummer, H.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Scientific Reports, 2018; 8(1):6483-1-6483-13
Statement of Responsibility
D. Christiansen, L. Earnest-Silveira, B. Chua, P. Meuleman, I. Boo, B. Grubor-Bauk, D.C. Jackson, Z.Y. Keck, S.K.H. Foung, H.E. Drummer, E.J. Gowans, J. Torresi
Conference Name
Abstract
The significant public health problem of Hepatitis C virus (HCV) has been partially addressed with the advent of directly acting antiviral agents (DAAs). However, the development of an effective preventative vaccine would have a significant impact on HCV incidence and would represent a major advance towards controlling and possibly eradicating HCV globally. We previously reported a genotype 1a HCV viral-like particle (VLP) vaccine that produced neutralizing antibodies (NAb) and T cell responses to HCV. To advance this approach, we produced a quadrivalent genotype 1a/1b/2a/3a HCV VLP vaccine to produce broader immune responses. We show that this quadrivalent vaccine produces antibody and NAb responses together with strong T and B cell responses in vaccinated mice. Moreover, selective neutralizing human monoclonal antibodies (HuMAbs) targeting conserved antigenic domain B and D epitopes of the E2 protein bound strongly to the HCV VLPs, suggesting that these critical epitopes are expressed on the surface of the particles. Our findings demonstrate that a quadrivalent HCV VLP based vaccine induces broad humoral and cellular immune responses that will be necessary for protection against HCV. Such a vaccine could provide a substantial addition to highly active antiviral drugs in eliminating HCV.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© The Author(s) 2018. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.